| Name | Title | Contact Details |
|---|
We are a Performance Improvement Consulting Firm Increase profitability and productivity with our proven Management System™. It is an accountability system that creates focus and alignment driving breakthrough results for your business. WHY WORK WITH US? 1. RESULTS Over 15,000 organizations and 170,000 business leaders accelerated their leadership and management performance through our proven MAP Management System™. 2. EXPERIENCE Our consultants are former CEOs and entrepreneurs with a track record of success who work with you every step of the way on business strategy and implementation. 3. LONGEVITY Weve been around since 1960 and worked on an incredibly diverse range of challenges across all industries and sizes. Are you ready to take your business to the next level?
Axolight is a lighting company, based in Italy and the United States, which designs and produces high-end decorative design lamps. Handmade in Italy Each Axolight product, whether it derives from mass production or from a customized request, is designed, developed, tested and assembled by hand at the company workshop in Venice - Scorzè.
One of the Worlds Largest Golf Simulator Companies, founded in South Korea in 2000. Winner of five consecutive Golf Digest Awards for Best Golf Simulator (2017-2021). We have over 9,449 sites worldwide, in 41 countries, with 47,500 simulators in operation. Over 99 million rounds are played annually.
PaulHood goes beyond basic tax preparation. We nurture all aspects of financial health, offering peace of mind and proactive solutions tailored to your unique individual and business needs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.